



NasoNeb-delivered Budesonide, (Pulmicort Respules® 0.25 mg/2ml), demonstrated statistically-significant objective and subjective outcomes in a peer-reviewed clinical study¹



NasoNeb-delivered Budesonide (Pulmicort Respules®, 0.25 mg/2ml) demonstrated a statistically-significant 50 LPM increase in daily nasal peak inspiratory flow (NPiF) from baseline to endpoint in the treatment arm of a parallel, randomized, double-blinded, placebo-controlled clinical trial in a perennial allergic rhinitis patient population.

Daily nasal peak inspiratory flow on treatment. Median values are depicted. The x-axis shows the study timeline with B = baseline measurement. *p < 0.005 vs baseline for the group on budesonide



Patients also reported statistically-significant improvements in total nasal symptoms scores (TNSS) and rhinoconjunctivitis quality of life scores.

Daily TNSS on treatment. Median values are depicted. The x-axis shows the study timeline with B = baseline measurement. *p < 0.05 vs respective baselines within treatment groups.

The authors concluded, in part: "... it stands to reason that administering intranasal corticosteroids, which have been shown effective time and again as a treatment for perennial allergic rhinitis, would prove to be even more effective when delivered in this novel way."

The NasoNeb System delivers proven outcomes.
Prescribe the NasoNeb Nasal Nebulizer for your sinus patients.

1. Kristal Brown, James Lane, Marianella Paz Silva, Marcy DeTineo, Robert M. Naclerio and Fuad M. Barody: "A pilot study of the effects of intranasal budesonide delivered by NasoNeb® on patients with perennial allergic rhinitis" *Int Forum Allergy Rhinol*, 2014; 4:43-48

